Compare · NVO vs SGMT
NVO vs SGMT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Sagimet Biosciences Inc. (SGMT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SGMT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $219.67B, about 496.8x SGMT ($442.1M).
- Over the past year, NVO is down 23.6% and SGMT is down 19.2% - SGMT leads by 4.4 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for SGMT).
- NVO has more recent analyst coverage (25 ratings vs 15 for SGMT).
- Company
- Novo Nordisk A/S
- Sagimet Biosciences Inc.
- Price
- $49.64-1.33%
- $7.15-8.68%
- Market cap
- $219.67B
- $442.1M
- 1M return
- +14.08%
- +9.33%
- 1Y return
- -23.56%
- -19.21%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 15
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SGMT
- Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
- Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Seidenberg Beth C
- SEC Form 4 filed by Director Hoelscher Paul W.
- SEC Form 4 filed by Director Jarrett Jennifer
- SEC Form 4 filed by Director Grammer Elizabeth A
- SEC Form 4 filed by Director Kemble George
- SEC Form 4 filed by Director Phillips Anne M.
- Sagimet Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Sagimet Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits